Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03435640 · ClinicalTrials.gov registry record · Phase 1
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
A Phase 1 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03435640 is a Phase 1 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 64 participants.
The verdict
NCT03435640, a Phase 1 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 results of the study, the decision was made not to start the Phase 2 part of the study and the study was terminated.
Interventions
- DRUG nivolumab
- DRUG NKTR-262
- DRUG bempegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2022-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03435640
The ClinicalTrials.gov registry entry for NCT03435640 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nivolumab is the first listed.
NCT03435640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03435640 about?
NCT03435640 is a clinical study titled "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies". Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 result...
What is the current status of trial NCT03435640?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-03-15. Estimated completion is 2022-05-09.
What interventions are being tested in trial NCT03435640?
The interventions under investigation include: nivolumab (DRUG), NKTR-262 (DRUG), bempegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT03435640?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.